Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ivabradine is a prescription hyperpolarization-activated cyclic nucleotide-gated channel blocker. It reduces the risk of hospitalization for worsening heart failure in selected adults with stable symptomatic chronic heart failure and treats stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients age 6 months and older.
read more about ivabradine ...Ivabradine inhibits the cardiac pacemaker current in the sinoatrial node. This slows spontaneous pacemaker activity and reduces heart rate without direct suppression of myocardial contractility.
Adult use is limited to stable symptomatic chronic heart failure with left ventricular ejection fraction of 35 percent or lower, sinus rhythm, and a resting heart rate of at least 70 beats per minute, with maximally tolerated beta-blocker treatment or a contraindication to beta-blockers. Pediatric treatment covers stable symptomatic heart failure due to dilated cardiomyopathy from age 6 months in sinus rhythm with an elevated heart rate.
The usual adult starting dose is 5 mg twice daily with food and can increase to 7.5 mg twice daily based on resting heart rate. Selected adults at greater risk from bradycardia start at 2.5 mg twice daily. Pediatric dosing depends on body weight and heart rate.
Ivabradine can cause fetal harm, atrial fibrillation, bradycardia, sinus arrest, and cardiac conduction disturbances. Strong CYP3A4 inhibitors are contraindicated. Other contraindications include acute decompensated heart failure, clinically significant low blood pressure or slow heart rate, severe liver impairment, and selected conduction disorders.
It reduces hospitalization risk from worsening heart failure in selected adults with stable symptomatic chronic heart failure.
The usual starting dose is 5 mg twice daily with food.
The maximum adult dose is 7.5 mg twice daily.
Yes. Current labeling states that ivabradine increases the risk of atrial fibrillation.
CORLANOR (Ivabradine) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92018a65-38f6-45f7-91d4-a34921b81d0d. Date Accessed October 5, 2026.
Ivabradine and Outcomes in Chronic Heart Failure (SHIFT): A Randomised Placebo-Controlled Study. https://pubmed.ncbi.nlm.nih.gov/20801500/. Date Accessed October 5, 2026.
Ivabradine Tablets Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5157767b-16d5-4a69-b6bd-95d360d19fda. Date Accessed October 5, 2026.
Ivabradine: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a615027.html. Date Accessed October 5, 2026.
Ivabradine. https://www.ncbi.nlm.nih.gov/books/NBK507783/. Date Accessed October 5, 2026.